临床试验生物样本库和存檔解决方案的全球市场：按产品、阶段和产品划分的市场规模和份额分析 - 产业需求预测（截至 2030 年）

全球临床生物样本库和檔案解决方案市场在 2023 年产生收入 39.852 亿美元，预计将以 8.2% 的复合年增长率增长，到 2030 年达到 69.166 亿美元。

这些市场趋势是由越来越多的公司提供各种服务以及外包储存和其他冷链流程的趋势推动的，以便将必要的资源集中在药物开发上。这是由于以下事实：它正在变得越来越强。

此外，储存和运输技术不断发展，结合生物储存的监管需求和该领域的当前趋势，可以极大地帮助节省金钱、时间和精力。

临床试验生物储存库和存檔解决方案产业正在蓬勃发展，使用的软体提供了复杂的实验室资讯管理系统的功能，该系统旨在支援实验室样本和资讯管理。这是由于用于编译数据以简化流程的廉价设备的可用性不断增加报告。

此外，在临床试验过程中会创建多方面的数据，这些资讯的管理和所有生物样本库程式使此类软体变得至关重要，从而为存檔解决方案的提供者创造了机会。

以阶段来看，III期类别在2023年占营收份额最大，为45%，预计未来将维持其主导地位。 这是因为 III 期研究使用大量标本和样本进行长期研究，导致对临床试验生物样本库和檔案解决方案的需求增加。

2023年，北美地区将占据最大份额，达到55%，预计该地区将继续占据主导地位。 这主要是由于临床试验数量的增加、全球市场领导者的存在以及该地区先进技术的使用。 此外，大量服务提供者、CRO 和生物製药公司的存在也增加了市场成长潜力。

因此，这种市场趋势是由提供各种服务的公司数量增加以及外包存储和其他冷链流程以将必要的资源集中在药物开发上的趋势不断增长所推动的。这可能是因为这已成为可能。

本报告分析了全球临床试验生物样本库和檔案解决方案市场，包括市场的基本结构和最新情况、主要推动和限制因素以及全球、按地区和主要国家的市场规模趋势。我们调查展望（基于金额，2017-2030）、按产品、阶段（阶段）和提供内容划分的详细趋势、市场竞争现状以及主要公司概况。

目录

第一章研究范围

第二章研究方法

第 3 章执行摘要

第 4 章市场指标

第五章产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/挑战
  • 促进/抑制因子影响分析
• 新型冠状病毒感染 (COVID-19) 的影响
• 波特五力分析

第六章世界市场

• 摘要
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：爱别（2017-2030 年）
• 市场收入：依产品划分（2017-2030 年）
• 市场收入：按地区划分（2017-2030 年）

第七章北美市场

• 摘要
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：爱别（2017-2030 年）
• 市场收入：依产品划分（2017-2030 年）
• 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第 11 章中东与非洲 (MEA) 市场

第12章美国市场

• 摘要
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：爱别（2017-2030 年）
• 市场收入：依产品划分（2017-2030 年）

第十三章加拿大市场

第14章德国市场

第十五章法国市场

第十六章英国市场

第十七章义大利市场

第十八章西班牙市场

第十九章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

• 市场参与者及其产品列表
• 主要公司的竞争基准
• 各大公司的产品基准
• 近期策略发展状况

第30章公司简介

• Azenta Life Sciences
• Thermo Fisher Scientific Inc.
• Precision Medicine Group LLC
• Medpace Inc.
• Labcorp Drug Development
• American Type Culture Collection
• IQVIA Inc.
• LabConnect Inc.

第31章附录

In 2023, the global clinical trial biorepository & archiving solutions market generated revenue of USD 3,985.2 million, which is expected to grow at a compound annual growth rate of 8.2% to reach USD 6,916.6 million by 2030.

This growth of the market can be credited to the rising count of companies offering an extensive variety of services and the growing trend of outsourcing storage and other cold-chain processes so that the essential resources can concentrate more on medicinal development.

Furthermore, storage and transport techs are constantly advancing, which, combined with the l regulatory needs on bio-storage and the present trends in this space, can enormously help in saving money, time, and effort.

The clinical trial biorepository & archiving solutions industry is rising quickly because of the improvement in the obtainability of less expensive devices to compile data, for streamline reporting, using software that provides the functionality of a combined laboratory information management system made to aid in managing laboratory samples and information.

Furthermore, multifaceted data is created during trials, and the managing of such information and all the biorepository procedures makes such software essential, therefore creating an opportunity for the providers of archiving solutions.

On the basis of phase, the phase III category accounted for the largest revenue share, of 45%, in 2023, and it is further expected to maintain its dominance in the future. It is due to the fact that a significant number of specimens and samples are used by Phase III studies for long-term research, leading to increased demand for biorepository and archive solutions from clinical trials.

In phase III of the clinical trial process, researchers and scientists will evaluate the efficacy and safety of novel treatments. The number of patients participating for a long time is very high among the majority of phase III clinical studies. Besides that, because of the high number of people involved for a long time, this stage is more likely to be affected by short- and long-term side effects.

In 2023, the North American region dominated the clinical trial biorepository & archiving solutions market with the largest share of 55%, and the region is also estimated to continue with the dominance in the future. This is mainly because of the rising number of clinical trials, the presence of global market leaders, and the usage of progressive techs in the region. Furthermore, the presence of a huge count of service providers, CROs, and biopharmaceutical businesses enhances the market growth potential.

Hence, this growth of the market can be credited to the rising count of companies offering an extensive variety of services and the growing trend of the outsourcing of storage and other cold-chain processes, so that the essential resources can concentrate more on medicinal development.

Top Providers of Clinical Trial Biorepository & Archiving Solutions Are:

Azenta US Inc.

Thermo Fisher Scientific Inc.

Precision Medicine Group LLC

Medpace Inc.

Labcorp Drug Development

American Type Culture Collection

IQVIA Inc.

LabConnect Inc.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by phase
  • 1.4.3. Market size breakdown, by offering
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Phase (2017-2030)
• 6.4. Market Revenue, by Offering (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Phase (2017-2030)
• 7.4. Market Revenue, by Offering (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Phase (2017-2030)
• 8.4. Market Revenue, by Offering (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Phase (2017-2030)
• 9.4. Market Revenue, by Offering (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Phase (2017-2030)
• 10.4. Market Revenue, by Offering (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Phase (2017-2030)
• 11.4. Market Revenue, by Offering (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Phase (2017-2030)
• 12.4. Market Revenue, by Offering (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Phase (2017-2030)
• 13.4. Market Revenue, by Offering (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Phase (2017-2030)
• 14.4. Market Revenue, by Offering (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Phase (2017-2030)
• 15.4. Market Revenue, by Offering (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Phase (2017-2030)
• 16.4. Market Revenue, by Offering (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Phase (2017-2030)
• 17.4. Market Revenue, by Offering (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Phase (2017-2030)
• 18.4. Market Revenue, by Offering (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Phase (2017-2030)
• 19.4. Market Revenue, by Offering (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Phase (2017-2030)
• 20.4. Market Revenue, by Offering (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Phase (2017-2030)
• 21.4. Market Revenue, by Offering (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Phase (2017-2030)
• 22.4. Market Revenue, by Offering (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Phase (2017-2030)
• 23.4. Market Revenue, by Offering (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Phase (2017-2030)
• 24.4. Market Revenue, by Offering (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Phase (2017-2030)
• 25.4. Market Revenue, by Offering (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Phase (2017-2030)
• 26.4. Market Revenue, by Offering (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Phase (2017-2030)
• 27.4. Market Revenue, by Offering (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Phase (2017-2030)
• 28.4. Market Revenue, by Offering (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Azenta Life Sciences
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Thermo Fisher Scientific Inc.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Precision Medicine Group LLC
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Medpace Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Labcorp Drug Development
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. American Type Culture Collection
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. IQVIA Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. LabConnect Inc.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports